Background: 5% minoxidil formulations twice daily are effective in treating vertex male androgenetic alopecia (AGA); however, efficacy and safety data in frontotemporal regions are lacking. Objectives: To assess the efficacy of 5% minoxidil topical foam (5% MTF) in the frontotemporal region of male AGA patients after 24 weeks of treatment compared to placebo treatment and to the vertex region. Methods: Seventy males with moderate AGA applied 5% MTF or placebo foam (plaTF) twice daily for 24 weeks in frontotemporal and vertex regions. Target area non-vellus hair count (TAHC) was the primary end point. Results: Frontotemporal and vertex TAHC and target area cumulative non-vellus hair width (TAHW) showed similar responses to 5% MTF with significant increases up to week 16 compared to baseline (p < 0.001). After 24 weeks of treatment, frontotemporal TAHW increased significantly in the 5% MTF group compared to the plaTF group (p = 0.017), while TAHC showed a similar non-significant increase from baseline in both regions. At 24 weeks, 5% MTF users rated a significant improvement in scalp coverage for the frontotemporal (p = 0.016) and vertex areas (p = 0.027). Conclusions: 5% MTF twice a day promotes hair density and width in both frontotemporal and vertex regions in men with moderate stages of AGA.

Han SH, Byun JW, Lee WS, Kang H, Kye YC, Kim KH, Kim DW, Kim MB, Kim SJ, Kim HO, Sim WY, Yoon TY, Huh CH, Hwang SS, Ro BI, Choi GS: Quality of life assessment in male patients with androgenetic alopecia: result of a prospective, multicenter study. Ann Dermatol 2012;24:311-318.
Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM, Tschen EH, Trancik RJ: A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2002;47:377-385.
Civatte J, Laux B, Simpson NB, Vickers CF: 2% topical minoxidil solution in male-pattern baldness: preliminary European results. Dermatologica 1987;175(suppl 2):42-49.
Olsen EA, Whiting D, Bergfeld W, Miller J, Hordinsky M, Wanser R, Zhang P, Kohut B: A multicenter, randomized, placebo-controlled, double-blind clinical trial of a novel formulation of 5% minoxidil topical foam versus placebo in the treatment of androgenetic alopecia in men. J Am Acad Dermatol 2007;57:767-774.
Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, Trakatelli M, Finner A, Kiesewetter F, Trueb R, Rzany B, Blume-Peytavi U, European Dermatology Forum: Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges 2011;9(suppl 6):S1-S57.
Blume-Peytavi U, Hillmann K, Dietz E, Canfield D, Garcia Bartels N: A randomized, single-blind trial of 5% minoxidil foam once daily versus 2% minoxidil solution twice daily in the treatment of androgenetic alopecia in women. J Am Acad Dermatol 2011;65:1126-1134.
Price VH, Menefee E, Strauss PC: Changes in hair weight and hair count in men with androgenetic alopecia, after application of 5 and 2% topical minoxidil, placebo, or no treatment. J Am Acad Dermatol 1999;41:717-721.
8. National Library of Medicine (US): Identifier NCT01319370, effectiveness and safety of minoxidil foam versus placebo foam for androgenetic alopecia. 2011 March 18.
Kohut B, Wanser R, Reardon R, Canfield W, Canfield D: A Methodology Study Comparing Traditional 35 mm Hair Counts to Automated Image Analysis Measurements, and Assessing Visualization Sensitivity of Hair Dyeing when Quantifying Hair Loss in Men and Women with Androgenetic Alopecia: Zurich, European Hair Research Society, 2005.
Canfield D: Photographic documentation of hair growth in androgenetic alopecia. Dermatol Clin 1996;14:713-721.
Lucky AW, Piacquadio DJ, Ditre CM, Dunlap F, Kantor I, Pandya AG, Savin RC, Tharp MD: A randomized, placebo-controlled trial of 5 and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol 2004;50:541-553.
Olsen EA, Weiner MS, Delong ER, Pinnell SR: Topical minoxidil in early male pattern baldness. J Am Acad Dermatol 1985;13:185-192.
DeVillez RL: Topical minoxidil for androgenetic alopecia: optimizing the chance for success by appropriate patient selection. Dermatologica 1987;175(suppl 2):50-53.
Arca E, Acikgoz G, Tastan HB, Kose O, Kurumlu Z: An open, randomized, comparative study of oral finasteride and 5% topical minoxidil in male androgenetic alopecia. Dermatology 2004;209:117-125.
Heinrich K, Heinrich U, Tronnier H: Influence of different cosmetic formulations on the human skin barrier. Skin Pharmacol Physiol 2014;27:141-147.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.